Back to Journals » Medical Devices: Evidence and Research » Volume 7

The clinical utility of FibroScan® as a noninvasive diagnostic test for liver disease

Authors Wilder J, Patel K

Received 14 February 2014

Accepted for publication 10 March 2014

Published 3 May 2014 Volume 2014:7 Pages 107—114


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Julius Wilder,1,2 Keyur Patel1,2

1Division of Gastroenterology, Duke University School of Medicine, 2Duke Clinical Research Institute, Durham, NC, USA

Abstract: An important aspect of managing chronic liver disease is assessing for evidence of fibrosis. Historically, this has been accomplished using liver biopsy, which is an invasive procedure associated with risk for complications and significant sampling and observer error, limiting the accuracy for determination of fibrosis stage. Hence, several serum biomarkers and imaging methods for noninvasive assessment of liver fibrosis have been developed. In this article, we review the current literature on an important noninvasive imaging modality to measure tissue elastography (FibroScan®). This ultrasound-based technique is now increasingly available in many countries and has been shown to be a reliable and safe noninvasive means of assessing disease severity in chronic liver disease of varying etiology.

Keywords: elastography, ultrasound, fibrosis, cirrhosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]